Eisai
Eisai Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs globally. The company operates primarily through its oncology and neurology business segments, focusing on complex diseases. Key products include targeted oncology treatments such as lenvatinib and therapeutic treatments for Alzheimer's disease such as lecanemab. Primary revenue drivers include sales of proprietary prescription pharmaceuticals across major geographic regions, including Japan, the United States, Europe, and Asia. Eisai holds a significant global market position, particularly within neurodegenerative disease therapeutics. The company is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
28 of the funds FundTelligence covers report a position in Eisai.
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 28
- Exposure themes
- Ageing & Longevity, Age-Related Disease, Neurodegeneration
Funds holding Eisai
- DWS Invest CROCI Japan — DWS · 3.56 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.88 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 0.35 % (full portfolio disclosed, October 2026)
- Danske Invest Japan Index Restricted — Danske Invest · 0.33 % (full portfolio disclosed, July 2026)
- Lannebo Marknad Japan — Lannebo · 0.12 % (full portfolio disclosed, June 2026)
- Storebrand Japan — Storebrand · 0.1 % (full portfolio disclosed, October 2026)
- KLP AksjeAsia Indeks — KLP · 0.08 % (full portfolio disclosed, June 2026)
- Handelsbanken Utviklede Markeder Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 28 funds holding it.